# Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

> **NCT00258297** · PHASE2 · TERMINATED · sponsor: **University of Rochester** · enrollment: 30 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** gefitinib
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** enzyme inhibitor therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** protein tyrosine kinase inhibitor therapy
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00258297
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Withdrawn for lack of funding and accrual
- **Last updated:** 2013-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258297, "Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00258297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*